(6I(2))-6-Hydroxy-3-oxoolean-12-en-28-oic acid | 32337-18-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: (6I(2))-6-Hydroxy-3-oxoolean-12-en-28-oic acid
• 英文别名: (4aS,6aR,6aS,6bR,8R,8aR,12aR,14bS)-8-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-10-oxo-3,4,5,6,6a,7,8,8a,11,12,13,14b-dodecahydro-1H-picene-4a-carboxylic acid
• CAS: 32337-18-1
• 化学式: C₃₀H₄₆O₄
• 分子量: 470.7
• InChiKey: GBMBQYFNPMVAMS-BOTRXSTOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  34
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.87
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Sweet Gum Fruit Extract as a Therapeutic Agent
  申请人：Liu Zhijun

  公开号：US20100189830A1

  公开（公告）日：2010-07-29

  Sweet gum ( Liquidambar styraciflua L., family Hamamelidaceae) fruit extract was discovered to possess potent activities against multiple targets of the PBK (phosphatidylinositide 3-kinase) pathway, especially the PI3K/Akt and mTOR pathways. At a very low concentration of 1.85 μg/ml (IC50), sweet gun extract showed the ability of simultaneously blocking the pathways of PI3K/Akt (upstream), mTOR (mammalian target of rapamycin) (downstream), as well as its downstream protein products S6K and S6. It was also able to block 5-HETE, a lipoxygenase product that contributes to inflammation and activation of PI3K/Akt. The sweet gum fruit extract was prepared with 50% methanol (47:1; raw to extract) and concentrated to an organic fraction (210:1 raw to extract) referred as LIS-100 via reverse-phase column chromatography using a bioassay directed fractionation approach. The extract is a new targeted therapeutic agent for numerous disorders known to be treated by mTOR inhibitors, including cancer, diabetes, obesity, and inflammation.
• [EN] SWEET GUM FRUIT EXTRACT AS A THERAPEUTIC AGENT<br/>[FR] EXTRAIT DE FRUIT DE LIQUIDAMBAR UTILISE COMME AGENT THERAPEUTIQUE
  申请人：UNIV LOUISIANA STATE

  公开号：WO2008144706A2

  公开（公告）日：2008-11-27

  [EN] Sweet gum (Liquidambar styraciflua L., family Hamamelidaceae) fruit extract was discovered to possess potent activities against multiple targets of the PBK (phosphatidylinositide 3-kinase) pathway, especially the PI3K/Akt and mTOR pathways. At a very low concentration of 1.85 µg/ml (IC50), sweet gun extract showed the ability of simultaneously blocking the pathways of PI3K/Akt (upstream), mTOR (mammalian target of rapamycin) (downstream), as well as its downstream protein products S6K and S6. It was also able to block 5-HETE, a lipoxygenase product that contributes to inflammation and activation of PI3K/Akt. The sweet gum fruit extract was prepared with 50% methanol (47: 1; raw to extract) and concentrated to an organic fraction (210: 1 raw to extract) referred as LIS-100 via reverse-phase column chromatography using a bioassay directed fractionation approach. The extract is a new targeted therapeutic agent for numerous disorders known to be treated by mTOR inhibitors, including cancer, diabetes, obesity, and inflammation.
  [FR] Selon l'invention, il a été établi qu'un extrait de fruit de liquidambar (Liquidambar styraciflua L., famille des hamamélidacées) présentait une activité puissante contre des cibles multiples de la voie PBK (phosphatidylinositide 3-kinase), en particulier les voies PI3K/Akt et mTOR. À une très faible concentration de 1,85 µg/ml (IC50), l'extrait de liquidambar présente la propriété de bloquer simultanément les voies de PI3K/Akt (amont), mTOR (cible mammifère de rapamycine) (aval), ainsi que ses produits protéiniques aval S6K et S6. Ledit extrait est également apte à bloquer 5-HETE, un produit de lipoxygénase qui contribue à l'inflammation et à l'activation de PI3K/Akt. L'extrait de fruit de liquidambar selon l'invention a été obtenu avec 50% de méthanol (47: 1; état brut-extrait) et concentré en une fraction organique (210: 1 état brut-extrait) appelée LIS-100 par chromatographie sur colonne en phases inversées, par la mise en oevre d'une approche de fractionnement dirigée par dosage biologique. L'extrait selon l'invention est un nouvel agent thérapeutique ciblé destiné à de nombreux troubles connus pour être sensibles à un traitement par inhibiteurs de mTOR, notamment le cancer, le diabète, l'obésité et les inflammations.